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Abstract
Background: Polymorphisms affecting Toll-like receptor (TLR) structure appear to be rare, as would be expected due to
their essential coordinator role in innate immunity. Here, we assess variation in TLR4 expression, rather than structure, as a
mechanism to diversify innate immune responses.
Methodology/Principal Findings: We sequenced the TLR4 promoter (4,3 kb) in Swedish blood donors. Since TLR4 plays a
vital role in susceptibility to urinary tract infection (UTI), promoter sequences were obtained from children with mild or
severe disease. We performed a case-control study of pediatric patients with asymptomatic bacteriuria (ABU) or those prone
to recurrent acute pyelonephritis (APN). Promoter activity of the single SNPs or multiple allelic changes corresponding to
the genotype patterns (GPs) was tested. We then conducted a replication study in an independent cohort of adult patients
with a history of childhood APN. Last, in vivo effects of the different GPs were examined after therapeutic intravesical
inoculation of 19 patients with Escherichia coli 83972. We identified in total eight TLR4 promoter sequence variants in the
Swedish control population, forming 19 haplotypes and 29 genotype patterns, some with effects on promoter activity.
Compared to symptomatic patients and healthy controls, ABU patients had fewer genotype patterns, and their promoter
sequence variants reduced TLR4 expression in response to infection. The ABU associated GPs also reduced innate immune
responses in patients who were subjected to therapeutic urinary E. coli tract inoculation.
Conclusions: The results suggest that genetic variation in the TLR4 promoter may be an essential, largely overlooked
mechanism to influence TLR4 expression and UTI susceptibility.
Citation: Ragnarsdo ´ttir B, Jo ¨nsson K, Urbano A, Gro ¨nberg-Hernandez J, Lutay N, et al. (2010) Toll-Like Receptor 4 Promoter Polymorphisms: Common TLR4
Variants May Protect against Severe Urinary Tract Infection. PLoS ONE 5(5): e10734. doi:10.1371/journal.pone.0010734
Editor: Carlos Penha-Goncalves, Instituto Gulbenkian de Cie ˆncia, Portugal
Received February 8, 2010; Accepted April 12, 2010; Published May 20, 2010
Copyright:  2010 Ragnarsdo ´ttir et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from the Swedish Medical Research Council, the Network of Excellence: EuroPathoGenomics, the Crafoord,
Wallenberg, Lundberg and Osterlund Foundations, the Blood and Defense Network (Faculty of Medicine, Lund University) and the Royal Physiografic Society. The
funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: catharina.svanborg@med.lu.se
¤a Current address: Department of Medical Microbiology, Institute of Laboratory Medicine, Lund University, Lund, Sweden
¤b Current address: Department of Clinical Sciences, Lund University, Malmo ¨ University Hospital, Malmo ¨, Sweden
Introduction
The innate immune response is essential for survival during
early stages of infection. Toll-like receptors (TLRs) are critical
sensors of microbial attack and effectors of the TLR dependent
innate defense enable the host to eliminate pathogens that
otherwise would cause disease or mortality [1,2,3]. The TLR
structure is relatively well conserved throughout evolution,
consistent with the involvement of specific TLR domains in
multiple, specific ligand interactions [4,5,6] and the recruitment to
the Toll/interleukin-1 receptor (TIR) signaling domain of adaptor
proteins, which are essential for TLR-signaling [5,7,8,9,10,11].
Given their crucial role as sentinels of the innate immune defense,
TLR structure and function are tightly regulated [12]. Numerous
attempts have been made to identify variation affecting TLR
structural genes and resulting disease susceptibility, but structural
gene polymorphisms are relatively rare [13] and their contribution
to human disease remains unclear.
UTIs are among the most common bacterial infections in man,
and remain a major cause of morbidity and mortality [14]. A
subset of disease-prone individuals is at risk for recurrent acute
pyelonephritis (APN), severe renal dysfunction and even end-stage
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been described in this patient group [15,16,17]. Asymptomatic
bacteriuria (ABU) is a more common condition than APN in most
age groups. Despite high bacterial numbers in urine .10
5 cfu/ml,
the patients do not develop symptoms and innate immune
responses to infection are low [18]. A molecular/genetic basis
for the low immune response in this patient group has not been
identified, however. In the murine UTI model, Tlr4 controls the
innate immune response to Escherichia coli and Tlr4
-/- mice develop
ABU rather than severe infection [19,20,21] suggesting that
reduced mucosal Tlr4 function may protect the host against
symptomatic infection. Low TLR4 expression levels were also
observed in children with ABU [22], thus supporting the relevance
to human disease of the observations in the murine model.
In this study, we examined whether differences in TLR4
expression levels may result from TLR4 promoter sequence
variation and if diversity of innate immune responses could be
attributed to variant TLR4 expression. The results indicate that
TLR4 expression levels influence the innate immunity response
and potentially link TLR4 promoter sequence variation to human
disease susceptibility.
Methods
Patients and controls
To investigate if TLR4 promoter variation might influence UTI
susceptibility, we enrolled two highly selected, UTI prone study
populations with a long history of either acute pyelonephritis
(APN) or asymptomatic bacteriuria (ABU) in childhood (The
clinical characteristics of patients and controls included in this
study are provided in supplementary table 1 (Table S1)). The
patients in study 1 were selected from all children with UTI, who
were being referred to one pediatric nephrologist (DK) and
followed for at least six years at the Department of Pediatrics,
Lund University Hospital. The diagnosis of APN was based on a
febrile infection ($38.5uC) with significant bacteriuria, C-reactive
protein (CRP) .20 mg/l and lack of symptoms of other infections.
A diagnosis of asymptomatic bacteriuria was based on at least
three consecutive urine cultures yielding the same bacterial strain
(.10
5 cfu/ml of urine) in a child with no symptoms of UTI and no
CRP increase. Patients with no evidence of symptomatic UTI
were assigned to the primary ABU group (7 boys and 9 girls,
median age 5, range ,1–20). Children who developed ABU after
having completed antibacterial therapy for a prior symptomatic
infection but with no further symptomatic episodes were assigned
to the secondary ABU group (4 boys and 10 girls, median age 7,
range 1–13). The APN group comprised 21 children (3 boys and
18 girls, median age 8.5 years at blood sampling, range ,1–17
years) with a history of APN, who had not developed ABU at any
time during follow-up.
Study 2 included 62 adult white patients with a history of
childhood APN, who participated in a study of febrile UTI in the
1970ies and were reinvestigated to evaluate genetic associations
between UTI morbidity and long-term effects of these infections
on health and kidney function, about 30 years after the initial UTI
episode [23]. Patients in this group, who consistently developed
APN, were assigned to the APN group, while patients who
developed ABU secondary to an APN episode were assigned to the
secondary ABU group.
Pediatric age-matched controls (n=39) were enrolled at the
pediatric outpatient clinic or when admitted for elective surgery
for diagnoses unrelated to infection. They had negative urine
cultures at the time of sampling and no recorded history of UTI.
The controls were white and the families were not consanguin-
eous. Adult healthy blood donors (n=200) from southern Sweden
were included to assess TLR4 sequence variation in the
population.
Informed written consent was obtained from all participants or
their parents/guardians. The study was approved by the Ethics
Committee of the medical faculty, Lund University, Sweden
(LU106-02, LU236-99).
Human therapeutic inoculation protocol
The prototypic ABU Escherichia coli strain 83972 has been
extensively used for therapeutic urinary bladder colonization in
patients with dysfunctional voiding and chronic UTI
[18,24,25,26,27]. Briefly, the patient is treated with appropriate
antibiotics if needed to eliminate pre-existing bacteriuria. After an
antibiotic free interval, the patient is catheterized, 30 ml of E. coli
83972 (10
5 cfu/ml) is instilled, and the catheter is removed. The
patients in this study (n=15) had neurogenic bladder disorders
and a history of recurrent UTI (3–4 UTI/year) during the last two
years but no APN episodes. Bacterial inoculations were performed
at the Urology Out-Patient Department, Lund University Hospital
under rigorous control and no adverse effects were observed.
Urine samples were obtained prior to and at standardized times
after inoculation, for bacterial culture, verification of E. coli 83972
bacteriuria and for quantification of neutrophil numbers with
Bu ¨rker chamber and Interleukin-6 (IL-6) and IL-8 levels by
Immulite.
Genomic DNA sampling
Genomic DNA was extracted from heparinised peripheral
blood using QIAamp DNA Blood Midi kit. Primers were designed
according to the published sequence for the TLR4 promoter,
starting 4.3 kb upstream of the ATG start codon (GenBank
accession number: AF177765). Genomic DNA was PCR amplified
and purified with a QIAquick PCR purification kit (Qiagen,
Hilden, Germany) before being sequenced in both directions using
nested primers (All primers are listed in Table S2. Patient
sequences were base called and multi-aligned along with control
sequences using PolyPhred and Phrap [28], visualized and
manually compared using Consed [29]. Sequencing was done
on a MegaBACE 1000 using a DYEnamic
TM ET Dye Terminator
kit (Megabace
TM) (Amersham Pharmacia Biotech).
Pyrosequencing
The TLR4 promoter variants detected by sequencing were
confirmed on a Pyrosequencer PSQ 96 using a PSQ 96 SNP
Reagent kit (Qiagen) and their frequency in the different patient
groups was determined. The pyrosequencing primers were
designed as shown in table S2 and used according to the
manufacturer’s instructions (Biotage).
Genotype vector constructs
A 4.3-kb genomic DNA fragment comprising the human TLR4
promoter was amplified from one patient with genotype pattern
GPIV, the predominant GP in the Swedish population, using the
Fermentas High Fidelity PCR system (29). In the heterozygote
positions, the clone carried the minor allele as confirmed by
sequencing. The product was cleaned with QIAquick PCR
purification kit (Qiagen, Hilden, Germany), NcoI-cleaved and
ligated into a NcoI-cleaved SAP-dephosphorylated pGL3basic
vector. To create single mutations or multiple allelic variants,
QuickChange XL site-directed mutagenesis kit (Stratagene) was
used (The primers and cloning scheme for the different constructs
is described in table S3).
UTIs and the TLR4 Promoter
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system assay
A498 renal carcinoma cells were cultured in 6-well plates in
RPMI 1640 medium (5% FCS) at a density of 5610
5 cells per well.
The cells were transiently transfected at 80% confluency using
Fugene HD with the wild-type or mutant hTLR4 promoter
constructs (4:2), as well as an internal renilla luciferase control
plasmid (pRL-TK) (Promega). Light emissions of firefly and renilla
luciferase were measured using the Dual Luciferase Reporter
System Assay (Promega). The firefly luciferase data was normal-
ized against the Renilla luciferase.
To examine the response of the TLR4 promoters to infection,
the A498 human kidney cell line was exposed for 4 hrs to 10
8 cfu/
ml of the prototype uropathogenic E. coli strain CFT073, re-
suspended in PBS after overnight growth on LB agar.
Bioinformatics analysis of the TLR4 promoter
The human TLR4 promoter sequence was compared pair-wise
to the following sequences using BLAST [30]:
1. Pan troglodytes chromosome 9, reference assembly NC_
006476.2.
2. Bos taurus chromosome 8, reference assembly NC_007306.3.
3. Sus scrofa chromosome 1, reference assembly NC_010443.1.
4. Mus musculus chromosome 4, reference assembly NC_000070.5.
5. Rattus norvegicus chromosome 5, reference assembly NC_
005104.2.
Figure 1B, C is based on BOV [31].
Statistical analysis
Allele frequencies were calculated and tested for agreement with
Hardy-Weinberg equilibrium using the | 2-goodness-of-fit test with
two degrees of freedom or Fisher’s exact test. Case and control
subjects were compared using the contingency | 2 test for
independence or Fisher’s exact test depending on the numbers.
Linkage disequilibria (LD) are displayed graphically using visual
genotype (VG) (http://pga.gs.washington.edu/VG2.html). Haplo-
type frequencies were calculated using the Expectation-Maximation
(EM) algorithm, implemented in PowerMarker. Expression levels
were compared using GraphPad InStat for Windows (version 3.06;
GraphPad Software). TFSEARCH was used for in silico predictions
of transcription factor binding sites, with a default threshold score of
85.0 (http://www.cbrc.jp/research/db/TFSEARCH.html).
Results
I. TLR4 promoter SNPs in the Swedish Population
Single nucleotide polymorphisms (SNPs) in the human
TLR4 promoter. We determined TLR4 promoter and
upstream region sequences by direct sequencing of amplified
PCR products and identified eight sequence variants in the
Swedish population, located at -4038, -3612, -3002 -2604, -2570,
-2081, -2026 and -1607 bp (Figure 1A). Four sequence variants
are novel (-4038, -3612, -3002, -2604), while four have been
described (-2081=rs10983755 and -1607=rs10759932 in the
NCBI SNP database and -1607, -2570 and -2026 in De Staercke et
al. [32]). Six of the eight SNPs had minor allele frequencies .5%
(Table S5), while SNPs -3002 and -2081 had minor allele
frequency of 1% and 4%. Control markers for all genotypes
were in Hardy-Weinberg equilibrium (x
2-test).
The overall conservation of TLR4 upstream sequences was
examined, by comparing the human reference sequence to known
sequences from chimpanzee, cow, pig, mouse and rat. Conserved
blocks showing at least 70% sequence identity to the human
promoter were identified (Figures 1B,C and table S6). The
chimpanzee promoter contained the eight sequence variants
(Table S6) but the other species showed less homology, especially
the mouse and rat (Figure 1B,C). Thus, even though TLR4 is
highly conserved from Drosophila to man, the region upstream of
the proximal TLR4 promoter has undergone substantial evolution
in the mammalian lineage.
Pair-wise LDs analysis (Figure 1D) showed that only SNPs
-4038 and -3612 were in complete LD (r
2=1.00), indicating that
they have not been separated by recombination or recurrent
mutation. Furthermore, SNPs -2570 and -2026 were in strong LD
(r
2=0.92). However, most of the TLR4 upstream promoter SNPs
were not strongly linked indicating that this region may have
undergone multiple recombination/mutation events and that gene
conversion might have occurred during evolution.
In silico predictions of possible transcription factor binding site
alterations were made, using TFSEARCH. Four of the eight SNPs
were located in sequences with high homology to transcription
factor binding motifs, while SNP -4038 and -2604 were suggested
to form new binding sites (Figure 1E). SNP -4038 created and
-2570-A/G potentially disrupted a binding site for CdxA, a
homeodomain protein, and Tst-1, a POU (Pit-Oct-Unc) domain
transcription factor which regulates early embryogenesis, neural
development and late viral genes during glia-specific human
papovavirus JC infection [33]. Variants -3612 and -3002 had no
predicted effect on transcription factor binding sites, but SNP
-2081 G/A disrupted a possible binding site for N-Myc, a basic
MYC family helix-loop-helix transcription factor that regulates
expression of many genes through Enhancer Box binding (E-
boxes). SNP -2026 A/G potentially disrupted sites for Oct-1 and
C/EBP, a CCAAT/enhancer protein. Oct-1, a POU domain
transcription factor, regulates a variety of tissue-specific and
general housekeeping genes by recruiting specialized transcrip-
tional co-activators. -1607 T/C was predicted to abrogate binding
of Nkx-2, a highly expressed homeobox transcription factor critical
during early cardiac development [34]. According to
TFSEARCH, conserved SNP -4038 and -2604 may form new
transcription factor binding sites (Figure 1E). SNP -4038 created a
potential CdxA site, while SNP -2604 formed a site for GATA-2, a
transcription factor in hematopoietic cells that has been implicated
as a negative regulator [35]. The in silico predictions thus suggest
mechanisms by which the TLR4 upstream region sequence
variants could affect TLR4 protein expression.
TLR4 promoter haplotype and genotype analysis. We
identified a total of 19 promoter haplotypes in the adult control
population (Figure 2); H1-4 accounted for more than 80%,
haplotypes 5 and 7 were found in 3% and 2%, respectively. The
remaining haplotypes each occurred in less than 1% of the
individuals.
Genotype patterns (GPs) were assigned by combining multiple
SNPs in each individual (Figure 3A). Twenty combinations of
multiple SNPs (GPs I-XX) were distinguished. GP IV was the most
common (25%) followed by GP XIII (17%), GP VII (8.5%), GP VI
(7%) and GP IX in 6% of the population (Figure 3B, table S7).
The remaining GPs were present in less than 3% of the
population, including GP II, the previously defined promoter
sequence described in AF177765 (,1%).
II. Disease associated TLR4 promoter SNPs in patients
with UTI
Since TLR4 plays a vital role in UTI susceptibility, we
examined TLR4 promoter sequences in two groups of highly
UTIs and the TLR4 Promoter
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asymptomatic carriage or APN, which is the most severe form of
UTI. The patients were compared to pediatric and adult controls
without UTI.
Study 1. TLR4 promoter genotype variants in UTI-prone
children. This included children who either had a consistent
pattern of asymptomatic carriage (primary ABU) or APN during
at least 5 years of follow up. The TLR4 promoter variability
differed between asymptomatic carriers and controls or patients
with severe disease. Only six of the eight detected SNPs were
present (Table S4) in patients with primary ABU and this group
had fewer haplotypes than the controls. Haplotype 4 was
approximately 3x more common than the control groups
(p=0.0765; p=0.0504), while the frequency of haplotypes 1, 2
and 3 did not differ significantly (Figure 2). The primary ABU
patients had also a reduced number of GPs and the proportion of
specific GPs differed compared to the background population
(268 contingency table; p=0.0007) (Figure 3, 4). GP X was
significantly more common in the primary ABU group (Figure 2C,
p=0.0033), GPs V and VII were also more frequently found in
the primary ABU group compared to the control populations
(13% vs. 3% for both V and VII). GP IX, which accounted for
13% of pediatric controls, was absent in this group (Figure 3B, 4).
In contrast, the APN patient group carried the eight SNPs and
did not differ in SNP frequency from pediatric controls, except for
the heterozygote SNP -2081 (Table S4, p=0.03). They carried
four rare haplotypes (H9-H12) (p,0.05 and p=0.0008 when
compared to the control populations) but the frequency of GPs did
not differ compared to controls (Figure 3B, 4). The patients with
secondary ABU carried the eight SNPs; the rare -2570
homozygote, the rare homozygous at -1607 and SNP -2081
differed in frequency compared to pediatric controls (Table S4).
This increase in rare homozygous variants was also visible in the
haplotypes, which differed markedly between secondary ABU,
pediatric and adult controls (Figure 2). H5 was more frequent in
the secondary ABU group (11% vs. 0%; p=0.0170). GP XX was
exclusively found in secondary ABU (p=0.0356) and GPs X and
XIII were decreased. There was no significant difference in TLR4
promoter haplotypes, genotype frequencies or GP distribution
between adult and pediatric controls.
Study 2. TLR4 promoter genotype variants in UTI-prone
patients; 30 years follow up. To confirm the association
between TLR4 promoter genotype variants and UTI, we
examined a second, highly UTI prone population. The patients
had their first episode of febrile UTI in the 1970ies and were
reinvestigated after about 30 years, including genetic analysis. The
APN group was selected based on a consistent pattern of recurrent
APN without ABU and carried the same eight TLR4 promoter
SNPs as APN patients in study 1. Their genotype frequency varied
compared to controls at -2604 and -2570 (Table S4). Furthermore,
GPIX was more common than in the control group (Table S8,
p=0.0113) and H3 was slightly more common (Figure S1). In the
secondary ABU group no significant difference in genotype
frequency was observed compared to the control group, apart
from SNP-2570 which varied like the pediatric secondary ABU
group. In addition, like in the APN group GPIX was found in
higher frequency compared to the control population (p=0.0113)
(Figure 4, table S8). Furthermore, H3 was found in much higher
frequency than in the adult controls (Figure S1, p,0.0001), similar
trend was observed in the pediatric population (Figure S1).
The results propose a possible association between TLR4
promoter sequence variants, promoter GPs and UTI severity.
Furthermore, marked differences were observed between children
with primary ABU and APN.
III. TLR4 SNPs alter basic transcription efficiency and the
response to infection
To examine whether the promoter sequence variants influence
transcription efficiency, we constructed luciferase reporter plas-
mids carrying TLR4 promoter sequences with single or multiple
changes. The GPIV promoter (wildtype) was cloned and each of
the eight SNPs was introduced by infusion cloning methodology.
Human kidney cells were transfected either with the GPIV (wt) or
each of the eight SNPs (single SNP constructs). Multiple SNPs
representing the most common GPs were also introduced into the
GPIV background (multiple SNP constructs) and transfected into
human kidney cells. Promoter activity was determined as the
luciferase activity relative to a renilla control plasmid.
The single and multiple SNP constructs were shown to modify
luciferase expression levels. Five of the single SNP constructs
differed significantly from the GPIV control (p,0.05), while two
did not (-2570 and -1607) (Figure 5A). Primary ABU associated
multiple SNP constructs VI, VII and XX showed significantly
lower baseline TLR4 reporter expression levels, compared to IV
(p,0.05, Figure 5B).
The change in promoter activity after infection with the virulent
uro-pathogenic isolate E. coli CFT073 was examined by exposing
transfected human kidney cells to E. coli CFT073 (4 h), and
comparing luciferase levels before and after infection (Figure 5C
and D). The single SNP constructs for -2081 and -2026 showed
significantly higher luciferase reporter activity after stimulation
with CFT073, but the others showed no significant change. For
-2081 and -2026, TRANSFAC predicted loss of a potential
transcription factor binding site; N-Myc for -2081 and Oct-1 and
C/EBP for -2026. Multiple SNP constructs VII, IX, X and XIII
significantly reduced reporter activity post infection. Interestingly,
IX from the secondary ABU group showed the strongest decrease
in luciferase response after infection.
In silico predicted changes in transcription factor binding
resulting from the single or multiple SNPs are schematically
represented in Figure 5C and D. The analysis identified complex
relationships, potentially involving cross-modulation of repressive
and enhancing SNPs. For example, repressive SNPs -2570 and
-2604 which encode new transcription factor binding sites appear
to negatively modulate each other as seen in GP VI and VII. SNP
-4038, defined by acquisition of promoter activity, seems to modify
the SNP -2604 repressor in GP IV but prevailed over by SNP
-2570 in GPs X and IX. GP XX suggested that a consensus SNP
Figure 1. Polymorphisms in the promoter region of the TLR4 gene. A. Eight sequence variants were identified by direct sequencing of PCR
products from the distal promoter region of the human TLR4 gene, starting 4.3 kb upstream of the ATG start codon. SNPs were located at bp -4038,
-3612, -3002, -2604, -2570, -2081, -2026 and -1607. B-C. Conservation of the human TLR4 promoter compared to Bos Taurus and Sus scrofa (b) Rattus
norvegicus and Mus musculus (c). Polymorphisms in the human consensus sequence were defined by comparison with the gene bank sequence
(AF177765) and positions are indicated by ovals, numbered relative to the transcription start site in the human gene bank sequence. Filled ovals are
located on conserved sequence blocks. D. Pair-wise linkage disequilibria (LD) were calculated, using VG2 software. LD was measured using r
2 where
the color scheme presents the degree of LD (range 0.0 through 1.0) where the maximum LD value (r
2=1) corresponds to the upper boundary of the
color spectrum. E. In silico predictions of transcription factor binding using TFSEARCH. Five of the eight SNPs were located in sequences with a high
degree of homology to possible transcription factor binding motifs.
doi:10.1371/journal.pone.0010734.g001
UTIs and the TLR4 Promoter
PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10734Figure 2. Haplotype analysis of TLR4 promoter polymorphisms in pediatric UTI patients and controls. A. Circle diagram showing the
haplotype frequency in the UTI groups and controls. The ABU groups differed significantly from the pediatric controls and between the ABU and the APN
groups,buttherewasnodifferencebetweenthetwocontrolgroupsorbetweentheAPNandcontrols.B.Haplotypefrequencyinpatients andcontrols.H4
was more common in the primary and H5 in the secondary ABU patients. There was no difference haplotype frequency between APN and control groups.
doi:10.1371/journal.pone.0010734.g002
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However, further studies are needed to establish more precisely
the nature of these complex relationships.
IV. TLR4 promoter genotype and the innate immune
response to human therapeutic urinary tract inoculation
To examine if TLR4 promoter GPs influence innate immune
responses in vivo, in the human urinary tract, we determined the
SNPs and GPs of patients who were subjected to therapeutic
urinary tract inoculation with the ABU strain E. coli 83972
(Figure 6). The mucosal innate immune response to infection was
quantified in urine as the IL-6 and IL-8 concentrations and as
neutrophil (PMN) numbers. Responses were compared between
patients with ABU associated promoter GPs and patients with
GPIV; the common, not UTI associated control.
Patients with the primary ABU associated GPs (VII, X) showed
lower innate immune response than the GPIV controls; patients
with GPVII had lower neutrophil counts (p,0.0001) and IL-6
concentrations (p=0.0004) and the patient with GPX had lower
IL-6 levels (p=0.0212). Furthermore, the patients carrying other
GPs found in the primary ABU group (VI and XIII) had decreased
IL-8 and PMN responses. GPVI and VII had low baseline TLR4
Figure 3. TLR4 promoter genotypes. A. TLR4 promoter GPs. Each column represents a genotype and each row a polymorphic site. Common allele
homozygote (blue), heterozygote (red) and rare allele homozygote (yellow) are shown. Genotype patterns marked I-XX were found in $2 individuals,
while GPs marked with – were found in one individual. B. GP frequencies in UTI prone patients and controls (Fisher’s Exact Test). GPX was significantly
more common in the primary ABU group and GPs V and VII were slightly more common in primary ABU, while GP XX was more common in
secondary ABU. No difference in GP frequency was observed between the controls and the patients with APN but patients with APN group differed
significantly from those with ABU.
doi:10.1371/journal.pone.0010734.g003
UTIs and the TLR4 Promoter
PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10734Figure 4. TLR4 promoter genotype patterns (GPs) in UTI patient and control groups. A. GP distribution in pediatric (study 1) and adult
(study 2) patients and controls. The UTI groups differed significantly compared to controls, but there was no difference between the pediatric and
adult controls. B. The combined frequency of the most common GPs in primary ABU (GPs V, VI, VII, X, XIII) was compared to pediatric secondary ABU
(p. sec ABU), pediatric APN (p. APN) and adult secondary ABU (a. sec ABU) or adult APN (a. APN)) groups.
doi:10.1371/journal.pone.0010734.g004
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PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10734Figure 5. TLR4 promoter GPs common in ABU patients reduce transcription efficiency. A-B. TLR4 promoter activity determined in a
luciferase reporter assay. Human renal carcinoma cells (A498) were transfected with plasmids carrying TLR4 promoter sequences in frame of a
luciferase reporter gene. The single SNP promoter constructs contained each of the detected SNPs. The multiple SNP constructs corresponding to
GPs in the primary or secondary ABU groups. Luciferase levels were compared to GPIV, which was most common in the population and unrelated to
UTIs and the TLR4 Promoter
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associated with asymptomatic status, relative to GPIV. Both GPs
showed significant decrease in two of the three immune response
parameters measured.
The results indicate that TLR4 promoter variation may
influence the mucosal response to E. coli infection.
Discussion
The marked differences in susceptibility to common infections
predict that there is substantial variation in the efficiency of the
antimicrobial defense within the population. Yet, the mechanisms
underlying exaggerated or attenuated host responses to many
common infections remain unclear. As TLR4 is essential for
innate immunity, understanding the genetic basis of varied TLR4
receptor expression and function is of great importance for the
many biological endpoints that depend on TLR4 signaling. We
describe a new concept for human TLR variation, based on TLR4
promoter polymorphisms that influence expression dynamics in
vitro and innate immune response dynamics in patients with ABU.
The results suggest that reduced TLR4 expression attenuates the
innate mucosal response, thus promoting an asymptomatic carrier
state rather than severe disease.
We show that the TLR4 promoter region is considerably more
variable than previously known, in contrast to many other genes,
where the overall variability is limited and closely positioned SNPs
usually belong to the same or a small number of haplotypes.
Interspecies comparisons of the TLR4 promoter region confirmed
this variability, as the sequences were poorly conserved except in
the chimpanzee and a few blocks in human, cow and pig genomes.
The few GPs in the primary ABU group might thus reflect
selection for low responder variants, which protect from severe
UTI, as shown in Tlr4
-/- mutant mice, and possibly from other
mucosal infections, where the host defense relies on TLR4
signaling.
The TLR4 promoter is lacking TATA and CAT boxes and GC-
rich motifs, which are typical for housekeeping gene promoters.
Instead the TLR4 promoter contains multiple binding sites for
PU.1 and different cis-regulatory sequences may influence the
transcription [36,37]. Variations in expression levels have not been
investigated, however. Previously, low TLR4 expression has
mostly been attributed to tolerance and not to genetic variation
affecting TLR4 expression. Michel et al. found no association
between TLR4 promoter polymorphisms and systemic inflamma-
tory markers for LPS-induced systemic inflammation [38]. De
Staercke et al. tried to link TLR4 promoter polymorphisms to
myocardial infarction risk but found no association [32]. This
study is therefore the first to propose that genetic variation in the
TLR4 promoter influences TLR4 expression.
We also showed that single and multiple SNPs mostly
suppressed TLR4 promoter activity in vitro and especially the
response to E. coli infection. The mechanism of TLR4 activation
by uropathogenic E. coli has been extensively studied in human
cells and animal models [39]. Our early studies in C3H/HeJ mice
showed that they developed ABU rather than APN, suggesting
that a functional Tlr4 response is essential for inflammation and
disease [19]. TLR4 was subsequently shown to control the
response to infection of epithelial cells lining the urinary tract
mucosa [21,26]. While UPEC rely on many different mechanisms
of host attack [40], TLR4 signalling is activated by P fimbrial
binding to cell surface glycosphingolipid receptors [41] and
ceramide acts as a signalling intermediate, activating TLR4
[42,43]. In the human therapeutic inoculation model, P fimbriae
were shown to promote the establishment of bacteriuria and
mucosal inflammation [21,26]. The observation that TLR4
promoter sequence variation may influence the clinical presenta-
tion of UTI is consistent with these earlier studies.
For a long time, UTI susceptibility has mainly been discussed in
terms of social and environmental factors or dysfunctional voiding
[44,45,46,47]. Now it is clear that genetic variation influences UTI
susceptibility, determined by the severity of acute infection as well
as the long-term effects on renal tissue integrity. Mice lacking the
murine chemokine receptor 2 (mCxcr2
-/-) develop APN with
urosepsis and progressive renal scarring [15,48]. The human
correlate is reduced CXCR1 expression in APN prone patients,
associated with heterozygous CXCR1 sequence variants [15,16].
In contrast, there is no evidence that specific immune dysfunctions
contribute to basic UTI susceptibility, in TCR mutant, RAG and
SCID mice and there is no evidence of increased UTI
susceptibility in patients with hypo-gammaglobulinemia or T cell
deficiencies [49,50]. Furthermore, Karoly et al. showed that
patients with UTI had higher prevalence of TLR4 SNP
Asp299Gly than controls (p=0,041). The SNP tended to occur
more frequently in patients with recurrent UTI without VUR than
in patients with vesicoureteral abnormalities (p=0,067) [51].
Hawn et al. suggested that Asp299Gly was associated with
protection from recurrent UTI, but not pyelonephritis. Further-
more, they showed that a TLR5_(C1174T) polymorphism was
associated with an increased risk of recurrent UTI but not
pyelonephritis, while a polymorphism in TLR1_(G1805T) was
associated with protection from pyelonephritis [52]. Furthermore,
a recent study by the same group reported that a TLR2_(G2258A)
polymorphism, which has been associated with decreased
lipopeptide-induced signaling, was associated with increased
ABU risk [53]. This current study adds TLR4 promoter sequence
variation to the list of human genetic variants influencing UTI
susceptibility, further emphasizing the importance of innate
immune regulation in UTI.
The present study also proposes that distinct genetic traits might
distinguish asymptomatic carriers from patients with symptomatic
UTI. While we are aware that genetic association analyses usually
are based on thousands of samples, a different approach was taken.
We used long-term follow up combined with selection to define
highly disease prone individuals. The two unique long-term
follow-up protocols both started in childhood, when UTI
susceptibility is diagnosed and lasted until it was possible to
distinguish patients with a clear pattern of APN from those who
developed ABU. This approach allowed us to observe significant
differences between relatively small groups of patients with
different forms of UTI, indicating that the patient material is
informative. This level of clinical definition is quite demanding,
but in suitable translational environments where candidate genes
UTI susceptibility. All transfected cells showed increased promoter activity compared to the background (Ba) control (means of three independent
experiments, mean+/2 SEMs). C-D. Change in promoter activity after infection with the uropathogenic E. coli strain CFT073 and schematic diagram
showing possible transcription factor binding sites. The change in promoter activity after E. coli CFT073 infection is shown relative to the GPIV control.
The histogram shows the fold difference in promoter activity post-infection for ABU-associated GPs and for the corresponding single SNPs. SNPs VII,
X, XIII and IX significantly reduced promoter activity in response to infection. SNPs -2081 and -2026 significantly increased luciferase activity while
-2604 and -2570 reduced the response to infection. (*=significant, ns=not significant, compared to uninfected cells carrying the same plasmids,
Student T test).
doi:10.1371/journal.pone.0010734.g005
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PLoS ONE | www.plosone.org 10 May 2010 | Volume 5 | Issue 5 | e10734Figure 6. Primary ABU associated GPs lower innate immune response to therapeutic inoculation of UTI prone patients. (A) Patients
(n=15) were subjected to therapeutic intravesical inoculation with the prototype ABU strain E. coli 83972. The innate host response was quantified as
the neutrophil numbers (B), IL-8 (C) and IL-6 (D) concentrations in urine at various times after inoculation. The response of patients with the ABU
associated GPs (VI, VII, X, XIII) was compared to the most common and not UTI associated GPIV. Patients with the ABU associated GPs showed
decreased responses compared to the GPIV controls. Pat. = Individual patient number. N=number of samples from each patient.
doi:10.1371/journal.pone.0010734.g006
UTIs and the TLR4 Promoter
PLoS ONE | www.plosone.org 11 May 2010 | Volume 5 | Issue 5 | e10734are identified, this approach might prove useful to assess if such
genes may contribute to disease susceptibility.
The challenges for the innate immune system at mucosal
surfaces differ from those at systemic sites after bacterial invasion.
While pathogens are recognized and often defeated by the
antibacterial defense, asymptomatic carriage is the most common
outcome of host-parasite interaction, creating the type of symbiosis
seen with the commensal microflora. Asymptomatic E. coli
carriage is very common, occurring in 1% of girls, .2% of
pregnant women and .10% of elderly individuals [54,55,56].
ABU has been shown to protect against infection with more
virulent bacteria [57], explaining why most clinical centers leave
ABU untreated. These observations have given rise to the use of
human therapeutic inoculation [26], which has been found safe
and efficient in open clinical studies and more recently in a
placebo-controlled study (Sunde ´n et al., In press in Journal of
Urology). It was therefore possible for us to examine if the innate
immune response in the urinary tract of several patients receiving
E. coli 83972 may reflect their TLR4 promoter genotypes. The
results supported this hypothesis, thus providing unique human
data suggesting that TLR4 promoter variation may be a significant
human innate immune variable.
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